The structure-activity relationships of organophosphorus (OP) and organosulfur compounds were examined in vitro and in vivo as inhibitors of mouse brain monoacylglycerol lipase (MAGL) hydrolysis of 2-arachidonoylglycerol (2-AG) and agonist binding at the CB1 receptor. Several compounds showed exceptional potency toward MAGL activity with IC 50 values of 0.1-10 nM in vitro and high inhibition at 10 mg/ kg intraperitoneally in mice. We find for the first time that MAGL activity is a major in vivo determinant of 2-AG and arachidonic acid levels not only in brain but also in spleen, lung, and liver. Apparent direct OP inhibition of CB1 agonist binding may be due instead to metabolic stabilization of 2-AG in brain membranes as the actual inhibitor.
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The endocannabinoids (EC) 2-arachidonoylglycerol (2-AG) and anandamide (AEA) regulate a diverse array of neurological and metabolic functions and are altered by neuropathic pain, anxiety, neurodegeneration, obesity, and cardiovascular disorders.
1 2-AG is a full agonist toward the cannabinoid receptor type 1 (CB1) and its signaling is terminated primarily by monoacylglycerol lipase (MAGL). AEA levels are regulated by fatty acid amide hydrolase (FAAH). 2-4 Augmentation of EC signaling by blockade of 2-AG or AEA degradation (Scheme 1) is proposed as a therapeutic strategy. However, characterization of MAGL or 2-AG in brain and peripheral tissues is hindered by the paucity of systemic MAGL inhibitors and lack of a MAGL knockout mouse. Discovery of potent MAGL inhibitors is therefore essential in understanding the biochemical, physiological, and therapeutic roles of this enzyme. Structural manipulation of organophosphorus (OP) and organosulfur (OS) compounds (Scheme 2) can potentially confer potency and selectivity for MAGL and FAAH compared to other serine hydrolases. OP 1 and OP 2 are previously reported as highly potent MAGL and FAAH inhibitors. 3, 4 However, some OPs and OSs also displace CB1 agonist binding through an unknown mechanism. This study reports structure-activity relationships of OPs and OSs with MAGL, FAAH, and CB1, and uses these tools to consider three interrelationships of the EC system components. The first is the in vitro potency for inhibiting MAGL, FAAH, and CB1 agonist binding as a predictor of in vivo behavioral effects and pharmacological profile. The second is the variation among tissues in their MAGL activity and differential regulation of 2-AG and AA levels. Finally, we consider the possibility that OP displacement of CB1 agonist binding is due to 2-AG in membranes which is metabolically stabilized by MAGL inhibition.
A library of 40 OPs and OSs, mostly prepared and optimized in the Berkeley laboratory, 7 was tested for potency and selectivity as inhibitors of MAGL, FAAH, and CB1 agonist binding in mouse brain membranes. 8 Five particularly potent OPs for all three targets were phosphonyl fluorides 1 and 2 and aryl phosphorus compounds 3-6, all with long alkyl substituents [n-C 12 H 25 P, arachidonyl (C 20 H 33 P) or n-C 9 H 19 SP] (Table 1 and Supplementary data). One diethyl phosphate insecticide metabolite (OP 7) was quite potent and another (OP 8) was only moderately active. Two sulfonyl fluorides (9 and 10) with long alkyl chains were very potent on FAAH, moderately active on MAGL, and differed greatly in activity on CB1. Eight potent in vitro inhibitors were administered intraperitoneally to mice at 10 mg/kg (OPs 1-6) or 100 mg/kg (OS 9 and OS 10) to determine if they were also effective in vivo in modulating behavior and brain 2-AG and arachidonic acid (AA) levels ( Fig. 1) . OP 1 and OP 4 were very effective in vivo in all respects, whereas OP 2 and OP 3 with similar in vitro potency to 1 and 4 were not effective in vivo. Thus, in vitro potency is not necessarily a predictor of in vivo activity with metabolic stability a likely contributor. OS 9 and OS 10 gave the same in vivo effects as OP 1 and OP 4 although at a 10-fold higher dose. Importantly, the OP-and OS-induced increase in brain 2-AG levels was always directly related to the lowering of brain free AA level.
2-AG and AA are important signaling molecules and intermediates not only in brain but also in other tissues.
1,2,11 OP 1 at 10 mg/ kg strongly inhibits brain MAGL activity, elevates 2-AG, and lowers AA, 4 suggesting that it might also do so in other tissues (Fig. 2) .
2-AG hydrolase activity was higher in brain than other tissues examined with 78-83% sensitive to OP 1 in vivo in brain, kidney, testes, pancreas, and liver and 92-99% OP 1-sensitive in vivo in heart, spleen, and lung. The apparent coupling of 2-AG and AA levels was also examined. Among the tissues analyzed, brain, spinal cord, liver, spleen, and lung, but not kidney, testes, pancreas, or heart showed the possible co-dependence of 2-AG and AA pools ( Fig. 2 and Supplementary data). Most tissues also had increased levels of other monoacylglycerol species, that is, 1-and 2-palmitoylglycerol and 1-and 2-oleoylglycerol (Supplementary data). Beyond changes in glycerol esters and AA levels, OP 1 treatment also led to decreases in other unesterified fatty acid levels (palmitic, oleic, or stearic acid) in spinal cord, liver, and spleen, indicating off-target effects of OP 1 in these tissues. The heart interestingly showed increases in both oleic and stearic acids (Supplementary data). 2-AG hydrolase activities and 2-AG and AA levels in mice treated with OP 1 (10 mg/kg, ip 4 h). 12 Values are expressed as means ± SD, n = 3 mice/treatment group. ND, not determined. Significance expressed as * p < 0.05, ** p < 0.01, *** p < 0.001 in unpaired Student's t-test.
Our results confirm the coordinate regulation of 2-AG and AA levels by MAGL in brain, 4 and show that this regulation also exists in some peripheral tissues. These findings disfavor the current model in which AA in many tissues is released primarily through glycerophospholipid metabolism via multiple phospholipase A2 enzymes, notably cytosolic PLA2 (cPLA2), secretory PLA2 (sPLA2), and calcium-independent PLA2 (iPLA2). While there are multiple studies correlating increased PLA2 expression to pro-inflammatory outcomes, cPLA2 À/À mice (also deficient in sPLA2) have identical levels of plasma and brain nonesterified fatty acid levels and brain acyl-coenzyme A levels, albeit there were changes in esterified phospholipid levels. 13 Although OP 1 is not completely selective for MAGL, it does not inhibit iPLA2 4 and the degree to which OPs 1, 4, 9, and 10 lower AA is equivalent to 2-AG elevation. MAGL inhibitors may help treat inflammatory diseases not only in brain but also in multiple peripheral tissues through the dual EC activation via 2-AG elevation and decreased eicosanoid signaling through AA reduction. It was very surprising to find that many OPs are potent inhibitors of CB1 agonist binding in brain membranes. One possible mechanism is direct OP binding or phosphorylation of CB1 at the agonist or an allosteric site, and another is indirect by OP inhibition of MAGL or FAAH to elevate the levels of 2-AG or AEA, or both which then serve as the inhibitor. Three lines of evidence suggest that the OPs do not react directly with CB1. Agonist binding is OP-sensitive in brain membranes but not in recombinant expressed CB1 (eCB1) 14, 15 (Fig. 3a) , indicating that some factor other than or in addition to CB1 is required. Covalently derivatized CB1 is not observed in brain membrane preparations labeled with a biotinylated fluorophosphonate probe under conditions in which phosphorylated MAGL and FAAH are readily evident. 4 Inhibition by OP derivatization is expected to be essentially irreversible and noncompetitive with the agonist, whereas inhibition by OP 7 gives an apparent competitive Scatchard plot ( Fig. 3b and Supplementary data). 16 An alternative hypothesis is that the OP inhibits MAGL and/or FAAH and elevates the 2-AG and/or AEA level which in turn blocks agonist binding (Schemes 1 and 3) . CB1, assayed as agonist binding with [ 3 H]CP55940, is highly sensitive to many OPs (Table 1 , Fig. 3a and b, and Supplementary data) and OP 1 potentiates the CB1 agonist action of 2-AG in vitro (measured by GTPcS binding) (Fig. 3c) . 17 OP 1 stimulates GTPcS binding at much higher concentration (EC 50 0.5 lM) (similar to the 0.3 lM EC 50 of 2-AG for CB1) 17 than that required to displace agonist binding (IC 50 2 nM) (Table 1) in similar preparations of brain membranes. The choice between MAGL/2-AG and FAAH/AEA as the target can be approached by OP sensitivity and specificity considerations, and by analysis for OP-induced elevations of EC levels. The OP sensitivity and specificity profiles correlate better for MAGL versus CB1 (r 2 = 0.81, n = 27) ( Fig. 3d) than for FAAH versus CB1 (r 2 = 0.68, n = 16) (Supplementary data).
Although AEA has higher CB1 affinity than 2-AG 18 , the $1000-fold greater level of 2-AG may override the affinity difference. Importantly, there is sufficient accumulation of 2-AG on OP treatment to strongly inhibit the CB1 site (Fig. 3e) . 19 These results support lipid rafts 20 as an important compartment for 2-AG in its interactions with CB1 and MAGL. The weight of evidence favors OP action on CB1 initiated by MAGL inhibition rather than FAAH inhibition or direct on the receptor.
In conclusion, we report the discovery of several OP MAGL inhibitors with unprecedented in vitro potency (IC 50 < 1 nM), a subset of which is effective in vivo in dramatically raising brain 2-AG levels, leading to cannabinoid behavior. These inhibitors are attractive probes to uncover specific functions of MAGL and 2-AG in EC signaling in vivo both centrally and peripherally, and to investigate MAGL as a therapeutic target. The findings establish that MAGL and 2-AG, and not phospholipases and phospholipids, regulate brain levels of free AA in multiple tissues. Finally, we propose a mechanism for OPs and other MAGL inhibitors to indirectly displace exogenous CB1 agonist binding in which elevated 2-AG levels, metabolically stabilized in brain membranes by MAGL inhibition, serve as the actual inhibitor. 
